Annual EBITDA
$25.68 M
+$213.31 M+113.68%
31 December 2023
Summary:
TG Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently $25.68 million, with the most recent change of +$213.31 million (+113.68%) on 31 December 2023. During the last 3 years, it has risen by +$298.36 million (+109.42%). TGTX annual EBITDA is now at all-time high.TGTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$15.10 M
+$4.50 M+42.45%
30 September 2024
Summary:
TG Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $15.10 million, with the most recent change of +$4.50 million (+42.45%) on 30 September 2024. Over the past year, it has dropped by -$102.67 million (-87.18%). TGTX quarterly EBITDA is now -87.18% below its all-time high of $117.77 million, reached on 30 September 2023.TGTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$5.89 M
-$102.67 M-94.58%
30 September 2024
Summary:
TG Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $5.89 million, with the most recent change of -$102.67 million (-94.58%) on 30 September 2024. Over the past year, it has increased by +$18.29 million (+147.48%). TGTX TTM EBITDA is now -94.58% below its all-time high of $108.56 million, reached on 30 June 2024.TGTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TGTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +113.7% | -87.2% | +147.5% |
| 3 y3 years | +109.4% | +117.9% | +101.8% |
| 5 y5 years | +114.9% | +125.0% | +103.2% |
TGTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +107.5% | -87.2% | +116.4% | -94.6% | +101.7% |
| 5 y | 5 years | at high | +107.5% | -87.2% | +116.4% | -94.6% | +101.7% |
| alltime | all time | at high | +107.5% | -87.2% | +116.4% | -94.6% | +101.7% |
TG Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $15.10 M(+42.5%) | $5.89 M(-94.6%) |
| June 2024 | - | $10.60 M(-227.6%) | $108.56 M(+100.8%) |
| Mar 2024 | - | -$8.31 M(-27.8%) | $54.06 M(+107.1%) |
| Dec 2023 | $25.68 M(-113.7%) | -$11.50 M(-109.8%) | $26.10 M(-310.4%) |
| Sept 2023 | - | $117.77 M(-368.3%) | -$12.40 M(-92.4%) |
| June 2023 | - | -$43.90 M(+21.0%) | -$164.21 M(+4.1%) |
| Mar 2023 | - | -$36.27 M(-27.5%) | -$157.68 M(-16.0%) |
| Dec 2022 | -$187.63 M(-45.1%) | -$50.01 M(+46.9%) | -$187.63 M(-18.3%) |
| Sept 2022 | - | -$34.04 M(-8.9%) | -$229.75 M(-18.0%) |
| June 2022 | - | -$37.36 M(-43.6%) | -$280.18 M(-12.3%) |
| Mar 2022 | - | -$66.22 M(-28.1%) | -$319.57 M(-6.5%) |
| Dec 2021 | -$341.97 M(+25.4%) | -$92.13 M(+9.1%) | -$341.97 M(+1.6%) |
| Sept 2021 | - | -$84.47 M(+10.1%) | -$336.66 M(-0.3%) |
| June 2021 | - | -$76.75 M(-13.4%) | -$337.65 M(+8.4%) |
| Mar 2021 | - | -$88.62 M(+2.1%) | -$311.46 M(+14.2%) |
| Dec 2020 | -$272.68 M(+63.0%) | -$86.82 M(+1.6%) | -$272.68 M(+22.0%) |
| Sept 2020 | - | -$85.46 M(+69.0%) | -$223.46 M(+12.7%) |
| June 2020 | - | -$50.57 M(+1.5%) | -$198.32 M(+8.5%) |
| Mar 2020 | - | -$49.83 M(+32.5%) | -$182.82 M(+9.3%) |
| Dec 2019 | -$167.30 M(-2.9%) | -$37.60 M(-37.7%) | -$167.30 M(-8.7%) |
| Sept 2019 | - | -$60.32 M(+72.0%) | -$183.28 M(+17.1%) |
| June 2019 | - | -$35.07 M(+2.2%) | -$156.57 M(-5.3%) |
| Mar 2019 | - | -$34.31 M(-36.0%) | -$165.40 M(-4.2%) |
| Dec 2018 | -$172.38 M(+46.8%) | -$53.58 M(+59.4%) | -$172.64 M(+16.0%) |
| Sept 2018 | - | -$33.61 M(-23.4%) | -$148.87 M(+1.4%) |
| June 2018 | - | -$43.90 M(+5.6%) | -$146.83 M(+11.8%) |
| Mar 2018 | - | -$41.56 M(+39.4%) | -$131.33 M(+11.8%) |
| Dec 2017 | -$117.42 M(+48.8%) | -$29.81 M(-5.6%) | -$117.42 M(+5.2%) |
| Sept 2017 | - | -$31.56 M(+11.1%) | -$111.62 M(+6.3%) |
| June 2017 | - | -$28.40 M(+2.7%) | -$104.96 M(+13.4%) |
| Mar 2017 | - | -$27.65 M(+15.2%) | -$92.57 M(+17.3%) |
| Dec 2016 | -$78.91 M(+24.9%) | -$24.01 M(-3.6%) | -$78.91 M(+7.4%) |
| Sept 2016 | - | -$24.91 M(+55.6%) | -$73.47 M(+18.6%) |
| June 2016 | - | -$16.01 M(+14.4%) | -$61.97 M(-1.3%) |
| Mar 2016 | - | -$13.99 M(-24.7%) | -$62.81 M(-0.6%) |
| Dec 2015 | -$63.16 M(+13.4%) | -$18.57 M(+38.5%) | -$63.16 M(-1.3%) |
| Sept 2015 | - | -$13.40 M(-20.5%) | -$64.03 M(-5.6%) |
| June 2015 | - | -$16.85 M(+17.5%) | -$67.84 M(+8.1%) |
| Mar 2015 | - | -$14.34 M(-26.2%) | -$62.73 M(+12.6%) |
| Dec 2014 | -$55.72 M(+185.4%) | -$19.43 M(+12.9%) | -$55.72 M(+33.6%) |
| Sept 2014 | - | -$17.22 M(+46.5%) | -$41.71 M(+44.8%) |
| June 2014 | - | -$11.75 M(+60.5%) | -$28.81 M(+23.1%) |
| Mar 2014 | - | -$7.32 M(+35.0%) | -$23.40 M(+19.9%) |
| Dec 2013 | -$19.52 M(-21.7%) | -$5.42 M(+25.7%) | -$19.52 M(+14.5%) |
| Sept 2013 | - | -$4.32 M(-32.0%) | -$17.04 M(+12.1%) |
| June 2013 | - | -$6.34 M(+84.3%) | -$15.21 M(+35.7%) |
| Mar 2013 | - | -$3.44 M(+17.0%) | -$11.21 M(-55.1%) |
| Dec 2012 | -$24.95 M(+2728.5%) | -$2.94 M(+18.6%) | -$24.95 M(+10.6%) |
| Sept 2012 | - | -$2.48 M(+5.8%) | -$22.56 M(+12.2%) |
| June 2012 | - | -$2.35 M(-86.3%) | -$20.11 M(+11.3%) |
| Mar 2012 | - | -$17.18 M(+2995.4%) | -$18.06 M(-5.7%) |
| Dec 2011 | -$882.00 K(-56.2%) | -$554.90 K(+1743.5%) | -$19.15 M(-12.2%) |
| Sept 2011 | - | -$30.10 K(-89.9%) | -$21.81 M(+2.0%) |
| June 2011 | - | -$297.00 K(-98.4%) | -$21.39 M(-1.0%) |
| Mar 2011 | - | -$18.27 M(+468.7%) | -$21.61 M(+458.0%) |
| Dec 2010 | -$2.01 M | -$3.21 M(-921.2%) | -$3.87 M(+286.9%) |
| Sept 2010 | - | $391.10 K(-174.7%) | -$1.00 M(-44.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$523.50 K(-1.0%) | -$1.79 M(+2.7%) |
| Mar 2010 | - | -$528.60 K(+55.4%) | -$1.74 M(-1.5%) |
| Dec 2009 | -$1.77 M(-59.7%) | -$340.10 K(-13.8%) | -$1.77 M(+28.8%) |
| Sept 2009 | - | -$394.40 K(-17.1%) | -$1.37 M(-41.7%) |
| June 2009 | - | -$475.80 K(-14.4%) | -$2.35 M(-29.5%) |
| Mar 2009 | - | -$555.80 K(-1108.7%) | -$3.34 M(-23.9%) |
| Dec 2008 | -$4.39 M(-63.7%) | $55.10 K(-104.0%) | -$4.39 M(-30.9%) |
| Sept 2008 | - | -$1.38 M(-5.7%) | -$6.35 M(-17.2%) |
| June 2008 | - | -$1.46 M(-9.1%) | -$7.67 M(-31.0%) |
| Mar 2008 | - | -$1.61 M(-15.9%) | -$11.12 M(-8.0%) |
| Dec 2007 | -$12.10 M(+21.7%) | -$1.91 M(-29.1%) | -$12.10 M(-9.4%) |
| Sept 2007 | - | -$2.70 M(-45.1%) | -$13.35 M(+5.9%) |
| June 2007 | - | -$4.91 M(+90.4%) | -$12.60 M(+25.6%) |
| Mar 2007 | - | -$2.58 M(-18.5%) | -$10.04 M(+1.0%) |
| Dec 2006 | -$9.94 M(-48.5%) | -$3.16 M(+62.3%) | -$9.94 M(-53.3%) |
| Sept 2006 | - | -$1.95 M(-16.7%) | -$21.29 M(+0.4%) |
| June 2006 | - | -$2.34 M(-5.6%) | -$21.20 M(+4.2%) |
| Mar 2006 | - | -$2.48 M(-82.9%) | -$20.35 M(+5.5%) |
| Dec 2005 | -$19.30 M(+220.9%) | -$14.51 M(+679.7%) | -$19.29 M(+195.7%) |
| Sept 2005 | - | -$1.86 M(+25.1%) | -$6.52 M(-5.0%) |
| June 2005 | - | -$1.49 M(+4.4%) | -$6.87 M(+8.5%) |
| Mar 2005 | - | -$1.42 M(-18.6%) | -$6.33 M(+5.2%) |
| Dec 2004 | -$6.01 M(+31.6%) | -$1.75 M(-20.6%) | -$6.01 M(+4.0%) |
| Sept 2004 | - | -$2.20 M(+131.5%) | -$5.78 M(+3.8%) |
| June 2004 | - | -$951.60 K(-14.3%) | -$5.57 M(+5.1%) |
| Mar 2004 | - | -$1.11 M(-26.9%) | -$5.30 M(+16.0%) |
| Dec 2003 | -$4.57 M(+359.0%) | -$1.52 M(-23.7%) | -$4.57 M(+58.5%) |
| Sept 2003 | - | -$1.99 M(+192.3%) | -$2.88 M(+94.6%) |
| June 2003 | - | -$680.80 K(+79.1%) | -$1.48 M(+41.2%) |
| Mar 2003 | - | -$380.20 K(-325.9%) | -$1.05 M(-18.5%) |
| Dec 2002 | -$995.50 K(-67.3%) | $168.30 K(-128.6%) | -$1.29 M(-35.7%) |
| Sept 2002 | - | -$588.20 K(+136.4%) | -$2.00 M(-5.0%) |
| June 2002 | - | -$248.80 K(-59.8%) | -$2.11 M(-36.4%) |
| Mar 2002 | - | -$618.40 K(+13.1%) | -$3.32 M(+14.5%) |
| Dec 2001 | -$3.04 M(-1.5%) | -$547.00 K(-21.1%) | -$2.89 M(>+9900.0%) |
| Sept 2001 | - | -$693.40 K(-52.4%) | -$5400.00(-97.9%) |
| June 2001 | - | -$1.46 M(+637.8%) | -$256.70 K(-86.4%) |
| Mar 2001 | - | -$197.40 K(-108.4%) | -$1.88 M(-38.7%) |
| Dec 2000 | -$3.09 M(+18.7%) | $2.34 M(-347.9%) | -$3.07 M(-48.9%) |
| Sept 2000 | - | -$944.70 K(-69.3%) | -$6.01 M(+8.0%) |
| June 2000 | - | -$3.08 M(+122.1%) | -$5.57 M(+74.7%) |
| Mar 2000 | - | -$1.39 M(+131.2%) | -$3.19 M(+13.8%) |
| Dec 1999 | -$2.60 M(-13.3%) | -$600.00 K(+20.0%) | -$2.80 M(-20.0%) |
| Sept 1999 | - | -$500.00 K(-28.6%) | -$3.50 M(-16.7%) |
| June 1999 | - | -$700.00 K(-30.0%) | -$4.20 M(+55.6%) |
| Mar 1999 | - | -$1.00 M(-23.1%) | -$2.70 M(-10.0%) |
| Dec 1998 | -$3.00 M(-42.3%) | -$1.30 M(+8.3%) | -$3.00 M(-9.1%) |
| Sept 1998 | - | -$1.20 M(-250.0%) | -$3.30 M(+6.5%) |
| June 1998 | - | $800.00 K(-161.5%) | -$3.10 M(-44.6%) |
| Mar 1998 | - | -$1.30 M(-18.8%) | -$5.60 M(+9.8%) |
| Dec 1997 | -$5.20 M(+40.5%) | -$1.60 M(+60.0%) | -$5.10 M(+10.9%) |
| Sept 1997 | - | -$1.00 M(-41.2%) | -$4.60 M(-2.1%) |
| June 1997 | - | -$1.70 M(+112.5%) | -$4.70 M(+30.6%) |
| Mar 1997 | - | -$800.00 K(-27.3%) | -$3.60 M(+33.3%) |
| Dec 1996 | -$3.70 M | -$1.10 M(0.0%) | -$2.70 M(+68.8%) |
| Sept 1996 | - | -$1.10 M(+83.3%) | -$1.60 M(+220.0%) |
| June 1996 | - | -$600.00 K(-700.0%) | -$500.00 K(-600.0%) |
| Mar 1996 | - | $100.00 K | $100.00 K |
FAQ
- What is TG Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for TG Therapeutics?
- What is TG Therapeutics annual EBITDA year-on-year change?
- What is TG Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for TG Therapeutics?
- What is TG Therapeutics quarterly EBITDA year-on-year change?
- What is TG Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for TG Therapeutics?
- What is TG Therapeutics TTM EBITDA year-on-year change?
What is TG Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TGTX is $25.68 M
What is the all time high annual EBITDA for TG Therapeutics?
TG Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $25.68 M
What is TG Therapeutics annual EBITDA year-on-year change?
Over the past year, TGTX annual earnings before interest, taxes, depreciation & amortization has changed by +$213.31 M (+113.68%)
What is TG Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TGTX is $15.10 M
What is the all time high quarterly EBITDA for TG Therapeutics?
TG Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $117.77 M
What is TG Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TGTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$102.67 M (-87.18%)
What is TG Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TGTX is $5.89 M
What is the all time high TTM EBITDA for TG Therapeutics?
TG Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $108.56 M
What is TG Therapeutics TTM EBITDA year-on-year change?
Over the past year, TGTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$18.29 M (+147.48%)